Abstracts tagged "rheumatic disease and treatment"

Abstract Number: 2421 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
Isabel Añón Oñate¹, Irene Notario¹, Miguel Ángel Ferrer¹, Lorena Pérez¹, María Ramírez¹ and Rafael Cáliz², ¹Rheumatology, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain
Background/Purpose: To evaluate the efficacy of the treatment on the pregnancy outcomes of women with Rheumatic Diseases and Thrombophilia from a Spanish cohort. Their pregnancies…
Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting
Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
L Tweehuysen¹, B.J.F. van den Bemt², I.L. van Ingen³, A.J.L. de Jong⁴, W.H. van der Laan⁵, F.H.J. van den Hoogen⁵ and A.A. den Broeder⁵, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Pharmacy, Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ³Rheumatology, Radboudumc Nijmegen, Nijmegen, Netherlands, ⁴Department of Rheumatology, Rijnstate Arnhem, Arnhem, Netherlands, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…
Abstract Number: 1233 • 2016 ACR/ARHP Annual Meeting
A Descriptive Analysis of Real-World Treatment Patterns of Innovator Infliximab (Remicade) and Biosimilar Infliximab in a Treatment NaïVe Turkish Rheumatologic Disease Population
Yusuf Yazici¹, Lin Xie², Adesuwa Ogbomo³, Dennis Parenti⁴, Kavitha Goyal⁴, Amanda Teeple⁴, Lorie A. Ellis⁵ and Ismail Simsek⁶, ¹New York University, Hospital of Joint Diseases, New York, NY, ²SATinMED Research, Ann Arbor, MI, ³STATinMED Research Inc., Ann Arbor, MI, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ⁶Guven Hospital, Ankara, Turkey
Background/Purpose: This retrospective healthcare claims analysis examined treatment patterns of innovator infliximab (IFX) and biosimilar infliximab (CT-P13) in a Turkish rheumatologic disease population after CT-P13…
Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Tara Landry¹, Mary-Ann Fitzcharles², Peter A. Ste-Marie³ and Yoram Shir³, ¹Montreal General Hospital Medical Library, Mcgill University Health Centre, Montreal, QC, Canada, ²Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].